Clint Carlson’s Hedge Fund Loses Its Chief Risk Officer in the Latest Senior Staff Departure to Rock the Firm (Business Insider)
Clint Carlson‘s Dallas-based hedge fund is losing another senior member of its team. Michael Palys, the $8.5 billion multi-strategy firm’s chief risk officer, submitted his resignation, a source close to the firm told Business Insider. He will be replaced by Jehan Akhtar, who has been with the firm since 2000, most recently as the head of derivatives. The departure comes at the end of a year when Carlson has also lost its longtime treasurer Michael Watson and head of fixed income Ivan Ross.
Activist Investor Launches Proxy Fight Against Luby’s (Chron.com)
A New York hedge fund this week officially launched a proxy fight to take control of Luby’s board of directors, which if successful would change the leadership of the struggling Houston restaurant chain helmed for nearly two decades by the Pappas brothers. Bandera Partners, which owns 9.5 percent of Luby’s stock, on Tuesday filed its preliminary proxy statement with the Securities and Exchange Commission, asking shareholders to elect four new candidates to Luby’s nine-member board. The hedge fund’s candidates are: Jeff Gramm, Bandera’s co-founder and portfolio manager; his father and former Sen. Phil Gramm of Texas; Stacy Hock, chairwoman of Texans for Education Opportunity; and Savneet Singh, managing partner of New York-based Tera Holdings.
Image By Monkey Business – Adobe
Hedge Funds On Track To Be Run Entirely By Anonymous Nobodies By End Of 2019 (DealBreaker)
Strictly speaking, this year doesn’t appear to be any worse for hedge funds than any other recent year. For the tenth in a row, they’re probably going to underperform the S&P 500. For the third in a row, more of them are likely to die than be born. Inflows are stagnant, but they have been since 2016. It’s a depressing picture, and all the more so given those giddy hopeful days in the wake of President Trump’s election, but such submediocrity has become the new normal. Just ask Steve Cohen. Still, even if hedge funds aren’t dying off at a particularly faster rate than in previous years, the ones that are have been particularly notable in 2018. T. Boone Pickens decided to hang up his hedge fundin’ spurs after 700 years in the business. Leon Cooperman, too.
Hedge Fund Employees Expect Fatter Paychecks in Beleaguered Year (Bloomberg)
Hedge fund employees of all stripes, from junior analysts to portfolio managers, have something in common this year: They’re all expecting fatter paychecks. Despite an industry beset with lagging performance, an investor exodus and closures, hedge fund professionals expect a median compensation of $520,000 in 2018, a 16 percent increase from last year, according to a survey by Odyssey Search Partners, an executive search firm based in New York.
Insider Buying: Fluidigm Co. (FLDM) Insider Buys $270,454.76 in Stock (PressOracle.com)
Fluidigm Co. (NASDAQ:FLDM) insider Levin Capital Strategies, L.P. purchased 35,033 shares of the firm’s stock in a transaction dated Monday, December 10th. The shares were bought at an average cost of $7.72 per share, with a total value of $270,454.76. The acquisition was disclosed in a filing with the SEC.
Insider Buying: TheStreet, Inc. (TST) Major Shareholder Purchases 627,220 Shares of Stock (WeekHerald.com)
TheStreet, Inc. (NASDAQ:TST) major shareholder Cannell Capital LLC acquired 627,220 shares of TheStreet stock in a transaction dated Tuesday, December 11th. The stock was purchased at an average cost of $2.05 per share, for a total transaction of $1,285,801.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission.
Insider Buying: Eidos Therapeutics Inc (NASDAQ:EIDX) Major Shareholder Buys 2,853,848 Shares of Stock (FairFieldCurrent.com)
Eidos Therapeutics Inc (NASDAQ:EIDX) major shareholder Bridgebio Pharma Llc purchased 2,853,848 shares of the firm’s stock in a transaction on Wednesday, December 5th. The stock was bought at an average cost of $14.92 per share, with a total value of $42,579,412.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Insider Buying: Arcimoto Inc (NASDAQ:FUV) CEO Acquires 139,903 Shares of Stock (MareaInformativa.com)
Arcimoto Inc (NASDAQ:FUV) CEO Mark Frohnmayer bought 139,903 shares of the stock in a transaction that occurred on Monday, November 19th. The stock was bought at an average price of $3.00 per share, with a total value of $419,709.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission.
Insider Buying: Platform Specialty Products Corp (PAH) Director Acquires $1,647,697.50 in Stock (PressOracle.com)
Platform Specialty Products Corp (NYSE:PAH) Director Martin E. Franklin bought 150,750 shares of the company’s stock in a transaction dated Monday, December 10th. The stock was purchased at an average cost of $10.93 per share, for a total transaction of $1,647,697.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission.
Insider Selling: AnaptysBio Inc (ANAB) CEO Sells 65,585 Shares of Stock (WeekHerald.com)
AnaptysBio Inc (NASDAQ:ANAB) CEO Hamza Suria sold 65,585 shares of AnaptysBio stock in a transaction on Wednesday, December 12th. The shares were sold at an average price of $71.47, for a total value of $4,687,359.95. Following the transaction, the chief executive officer now directly owns 65,649 shares of the company’s stock, valued at $4,691,934.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
